Novartis AG ADR (NVS)vsPrime Medicine, Inc. Common Stock (PRME)
NVS
Novartis AG ADR
$161.52
-1.40%
HEALTHCARE · Cap: $303.67B
PRME
Prime Medicine, Inc. Common Stock
$4.55
+2.48%
HEALTHCARE · Cap: $654.77M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1408297% more annual revenue ($57.36B vs $4.07M). NVS leads profitability with a 17.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
PRME
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$161.52
$65.96 premium
Margin of Safety
-44.4%
Fair Value
$2.39
Current Price
$4.55
$2.16 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
Trading at 19.8x book value
3.5% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : PRME
PRME has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : PRME
The primary concerns for PRME are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 2.83 is elevated, increasing financial risk.
Key Dynamics to Monitor
PRME carries more volatility with a beta of 2.38 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (48/100 vs 32/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Prime Medicine, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology, which enables precise DNA modifications. The firm has curated a diverse pipeline targeting severe diseases, including genetic disorders and various cancers, addressing substantial unmet medical needs within the healthcare system. With a strong intellectual property foundation and a commitment to developing innovative therapeutic solutions, Prime Medicine is strategically positioned for notable growth and has the potential to significantly change therapeutic approaches in the biopharmaceutical industry.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?